ENLVEnlivex Therapeutics Ltd.

Nasdaq enlivex.com


$ 1.44 $ -0.08 (-5.33 %)    

Friday, 28-Jun-2024 10:55:23 EDT
QQQ $ 479.98 $ -2.50 (-0.52 %)
DIA $ 391.11 $ -0.43 (-0.11 %)
SPY $ 544.70 $ -2.15 (-0.39 %)
TLT $ 91.77 $ -1.74 (-1.86 %)
GLD $ 215.03 $ 0.02 (0.01 %)
$ 1.42
$ 1.46
$ 1.42 x 100
$ 0.00 x 0
$ 1.44 - $ 1.46
$ 1.15 - $ 4.59
21,773
na
26.41M
$ 1.12
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 enlivex-doses-first-patient-in-a-randomized-placebo-controlled-phase-iii-trial-evaluating-allocetratm-in-up-to-46-patients-with-thumb-osteoarthritis

First patient dosed with AllocetraTM in thumb osteoarthritis, a degenerative, debilitating and progressive disease that affects...

 hc-wainwright--co-maintains-buy-on-enlivex-therapeutics-lowers-price-target-to-6

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Enlivex Therapeutics (NASDAQ:ENLV) with a Buy and lowers the pr...

 enlivex-receives-regulatory-authorization-for-the-initiation-of-a-placebo-controlled-phase-iii-trial-evaluating-allocetra-in-up-to-46-patients-with-thumb-osteoarthritis

 First study of AllocetraTM in thumb osteoarthritis, a debilitating disease that affects millions of people in the U.S., and ha...

 hc-wainwright--co-reiterates-buy-on-enlivex-therapeutics-maintains-7-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Enlivex Therapeutics (NASDAQ:ENLV) with a Buy and maintains $7...

 enlivex-announces-dosing-of-first-two-patients-in-its-randomized-controlled-phase-iii-trial-evaluating-allocetra-in-patients-with-knee-osteoarthritis

 Enlivex Therapeutics Ltd. (NASDAQ:ENLV, the "Company")))), a clinical-stage macrophage reprogramming immunotherapy com...

 tesla-to-180-here-are-10-top-analyst-forecasts-for-friday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...

 hc-wainwright--co-maintains-buy-on-enlivex-therapeutics-lowers-price-target-to-7

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Enlivex Therapeutics (NASDAQ:ENLV) with a Buy and lowers the pr...

 nasdaq-jumps-250-points-crude-oil-down-1

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite surging more than 250 points on Thursday. The D...

 why-fastenal-shares-are-trading-lower-by-around-7-here-are-other-stocks-moving-in-thursdays-mid-day-session

Shares of Fastenal Company (NASDAQ: FAST) fell sharply during Thursday’s session following worse-than-expected first-quarter f...

 dow-dips-100-points-carmax-earnings-miss-views

U.S. stocks traded mixed midway through trading, with the Dow Jones index falling around 100 points on Thursday.

 nasdaq-gains-over-50-points-us-producer-prices-increase-in-march

U.S. stocks traded mostly higher this morning, following the release of PPI data. Following the market opening Thursday, the D...

 enlivex-announces-topline-results-of-its-phase-ii-trial-evaluating-allocetra-in-patients-with-sepsis

Analysis of eligible1 patients from the sepsis Phase II study (NCT# NCT04612413) In accordance with the study protocol, the saf...

 enlivex-announces-issuance-of-new-us-patent-number-us-11883429-covering-allocetra-cells-and-their-manufacturing-method

Enlivex Therapeutics Ltd., (NASDAQ:ENLV, the "Company")))), a clinical-stage macrophage reprogramming immunotherapy com...

 enlivex-receives-imoh-authorization-for-initiation-of-multi-country-randomized-controlled-phase-iii-trial-evaluating-allocetra-in-up-to-160-patients-with-moderate-to-severe-knee-osteoarthritis

Second study of Allocetra in knee osteoarthritis, following the on-going Phase I/II trial in pre-surgery, end-stage osteoarthri...